Bladder cancer has been one of the most common tumor diseases in Europe. It usually affects the men and it can be an outcome of the lifestyle that they follow. But the higher numbers have always been a concern for not only doctors treating it but also to the researchers and scientists have been trying to find a better solution to aid patients.

Big relief for bladder cancer patients as researchers at the Max Planck Institute for infection biology, Berlin, Prof Stefan Kaufmann, and his team have modified the regular TB vaccine in a way that it stimulates the immune response. 
Taking into account the researches done in the 19th century which showed bacteria helps in shrinking the tumors.  Thus, it is comprehended that our resistant framework whenever bolstered can help battle against tumors which in the long run assists with diminishing the tumors.

Several Immunology researchers have also contributed with their expertise on this topic which has helped to develop VPM 1002.

This new vaccine VPM 1002 has not only better protection against TB but also can successfully be used to prevent the reoccurrence of tumors. Which has been successfully checked and half of the patients had no repeated symptoms. 
As we all understand that TB hampers immunity and so does cancer and hence this genetically modified vaccine BCG will be proved very beneficial for the patients. It is also claimed by Kaufman that it identifies the target much faster and better. This will help the patient to recover soon.

 
This has also encouraged a clinical study in Switzerland to check if it's possible to avoid removing bladders from patients' suffering from cancer of the bladder by using VPM1002. Further progress on this is yet to be confirmed from the European country.

This marks a huge scientific advancement in the medical world which will help not only Europeans but also will help patients across the globe. The vaccine has already been approved and started its production in the world's biggest vaccine manufacturer, the serum institute of India in collaboration with Valzine Projekt Management GmbH(VPM) from Hannover, Germany.

 India has started making samples ready for testing and soon it will be available for the masses. India is also keen to support its TB patients with the same vaccine which is on the higher number in comparison to other countries.